The association between dementia and serum adiponectin has been evaluated in many studies; however, conclusions remain mixed.
Objective:
We investigated the cross-sectional associations of adiponectin with cognitive function and Alzheimer’s disease (AD) biomarkers and whether serum adiponectin levels can predict cognitive outcomes.
Methods:
This study included 496 participants from the Alzheimer’s Disease Neuroimaging Initiative 1 (ADNI1) with available serum adiponectin levels at baseline and ≥65 years of age. Subjects were stratified based on sex and apolipoprotein ɛ4 (APOE4) carrier status to determine associations between adiponectin and cognitive function. The linear mixed model was used to analyze associations between adiponectin level and cognitive outcome in amnestic mild cognitive impairment (aMCI) patients.
Results:
Serum adiponectin levels were higher in aMCI and AD than in CN subjects among APOE4 non-carrier males (adiponectin in CN, aMCI, and AD: 0.54±0.24, 0.74±0.25, and 0.85±0.25, respectively, p < 0.001). In this group, serum adiponectin levels were associated with age (p = 0.001), ADAS13 (p < 0.001), memory function (p < 0.001), executive function (p < 0.001), total tau (p < 0.001), and phosphorylated tau (p < 0.001) measures in cerebrospinal fluid (CSF). Higher adiponectin level was not associated with cognitive outcome in aMCI patients in the linear mixed model analysis over 5.3±2.6 years of mean follow-up.
Conclusion:
Serum adiponectin level was associated with cognitive function and CSF AD biomarkers among APOE4 non-carrier males. However, serum adiponectin level was not associated with longitudinal cognitive function outcome in aMCI.
MullerM, TangMX, SchupfN, ManlyJJ, MayeuxR, LuchsingerJA (2007) Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord24, 185–192.
2.
WhitmerRA, GustafsonDR, Barrett-ConnorE, HaanMN, GundersonEP, YaffeK (2008) Central obesity and increased risk of dementia more than three decades later. Neurology71, 1057–1064.
3.
Brochu-GaudreauK, RehfeldtC, BlouinR, BordignonV, MurphyBD, PalinMF (2010) Adiponectin action from head to toe. Endocrine37, 11–32.
4.
WangZV, SchererPE (2016) Adiponectin, the past two decades. J Mol Cell Biol8, 93–100.
5.
ChandranM, PhillipsSA, CiaraldiT, HenryRR (2003) Adiponectin: More than just another fat cell hormone?Diabetes Care26, 2442–2450.
6.
van HimbergenTM, BeiserAS, AiM, SeshadriS, OtokozawaS, AuR, ThongtangN, WolfPA, SchaeferEJ (2012) Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: Results from the Framingham Heart Study. Arch Neurol69, 594–600.
7.
WennbergAM, GustafsonD, HagenCE, RobertsRO, KnopmanD, JackC, PetersenRC, MielkeMM (2016) Serum adiponectin levels, neuroimaging, and cognition in the Mayo Clinic Study of Aging. J Alzheimers Dis53, 573–581.
8.
RobertsRO, GedaYE, KnopmanDS, BoeveBF, ChristiansonTJ, PankratzVS, KulloIJ, TangalosEG, IvnikRJ, PetersenRC (2009) Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement5, 398–405.
9.
TeixeiraAL, DinizBS, CamposAC, MirandaAS, RochaNP, TalibLL, GattazWF, ForlenzaOV (2013) Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer’s disease. Neuromolecular Med15, 115–121.
10.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
11.
MohsRC, KnopmanD, PetersenRC, FerrisSH, ErnestoC, GrundmanM, SanoM, BieliauskasL, GeldmacherD, ClarkC, ThalLJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord11 Suppl 2, S13–21.
12.
CranePK, CarleA, GibbonsLE, InselP, MackinRS, GrossA, JonesRN, MukherjeeS, CurtisSM, HarveyD, WeinerM, MungasD (2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav6, 502–516.
13.
GibbonsLE, CarleAC, MackinRS, HarveyD, MukherjeeS, InselP, CurtisSM, MungasD, CranePK (2012) A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav6, 517–527.
LiuCC, LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
16.
ObataY, YamadaY, TakahiY, BadenMY, SaishoK, TambaS, YamamotoK, UmedaM, FurubayashiA, MatsuzawaY (2013) Relationship between serum adiponectin levels and age in healthy subjects and patients with type 2 diabetes. Clin Endocrinol (Oxf)79, 204–210.
17.
BöttnerA, KratzschJ, MüllerG, KapellenTM, BlüherS, KellerE, BlüherM, KiessW (2004) Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab89, 4053–4061.
18.
SnyderHM, AsthanaS, BainL, BrintonR, CraftS, DubalDB, EspelandMA, GatzM, MielkeMM, RaberJ, RappPR, YaffeK, CarrilloMC (2016) Sex biology contributions to vulnerability to Alzheimer’s disease: A think tank convened by the Women’s Alzheimer’s Research Initiative. Alzheimers Dement12, 1186–1196.
19.
ChêneG, BeiserA, AuR, PreisSR, WolfPA, DufouilC, SeshadriS (2015) Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement11, 310–320.
20.
LinKA, ChoudhuryKR, RathakrishnanBG, MarksDM, PetrellaJR, DoraiswamyPM (2015) Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y)1, 103–110.
21.
BarnesLL, WilsonRS, BieniasJL, SchneiderJA, EvansDA, BennettDA (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry62, 685–691.
22.
ArdekaniBA, ConvitA, BachmanAH (2016) Analysis of the MIRIAD data shows sex differences in hippocampal atrophy progression. J Alzheimers Dis50, 847–857.
23.
MielkeMM, VemuriP, RoccaWA (2014) Clinical epidemiology of Alzheimer’s disease: Assessing sex and gender differences. Clin Epidemiol6, 37–48.
24.
RuigrokAN, Salimi-KhorshidiG, LaiMC, Baron-CohenS, LombardoMV, TaitRJ, SucklingJ (2014) A meta-analysis of sex differences in human brain structure. Neurosci Biobehav Rev39, 34–50.
25.
LiR, SinghM (2014) Sex differences in cognitive impairment and Alzheimer’s disease. Front Neuroendocrinol35, 385–403.
26.
VestRS, PikeCJ (2013) Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav63, 301–307.
WaragaiM, AdameA, TrinhI, SekiyamaK, TakamatsuY, UneK, MasliahE, HashimotoM (2016) Possible involvement of adiponectin, the anti-diabetes molecule, in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis52, 1453–1459.
29.
UneK, TakeiYA, TomitaN, AsamuraT, OhruiT, FurukawaK, AraiH (2011) Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. Eur J Neurol18, 1006–1009.
30.
MaJ, ZhangW, WangHF, WangZX, JiangT, TanMS, YuJT, TanL (2016) Peripheral blood adipokines and insulin levels in patients with Alzheimer’s disease: A replication study and meta-analysis. Curr Alzheimer Res13, 223–233.
31.
AritaY, KiharaS, OuchiN, TakahashiM, MaedaK, MiyagawaJ, HottaK, ShimomuraI, NakamuraT, MiyaokaK, KuriyamaH, NishidaM, YamashitaS, OkuboK, MatsubaraK, MuraguchiM, OhmotoY, FunahashiT, MatsuzawaY (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun257, 79–83.
32.
BesserLM, GillDP, MonsellSE, BrenowitzW, MeranusDH, KukullW, GustafsonDR (2014) Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease. Alzheimer Dis Assoc Disord28, 36–43.
33.
FerranniniE, NataliA, BellP, Cavallo-PerinP, LalicN, MingroneG (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest100, 1166–1173.
SongJ, ChoiSM, WhitcombDJ, KimBC (2017) Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity. Cell Death Dis8, e3102.
39.
ZhangD, WangX, LuXY (2016) Adiponectin exerts neurotrophic effects on dendritic arborization, spinogenesis, and neurogenesis of the dentate gyrus of male mice. Endocrinology157, 2853–2869.
40.
NgRC, ChengOY, JianM, KwanJS, HoPW, ChengKK, YeungPK, ZhouLL, HooRL, ChungSK, XuA, LamKS, ChanKH (2016) Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice. Mol Neurodegener11, 71.
41.
KusminskiCM, McTernanPG, SchrawT, KosK, O’HareJP, AhimaR, KumarS, SchererPE (2007) Adiponectin complexes in human cerebrospinal fluid: Distinct complex distribution from serum. Diabetologia50, 634–642.
42.
JichaGA, ParisiJE, DicksonDW, JohnsonK, ChaR, IvnikRJ, TangalosEG, BoeveBF, KnopmanDS, BraakH, PetersenRC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol63, 674–681.
